These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36422802)

  • 1. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.
    Yabe D; Matsuhisa M; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2024 Mar; 15(3):705-723. PubMed ID: 38363541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan.
    Ishii H; Kamiya H; Takahashi Y; Morimoto Y; Yabe D
    Diabetes Ther; 2024 Nov; 15(11):2381-2400. PubMed ID: 39347902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
    Giorgino F; Caruso I; Napoli R
    Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.
    Đekić D; Bojić M; Janež A; Klobučar S; Hadžimušović IG; Ković T; Mihalevska S
    Diabetes Ther; 2023 Jul; 14(7):1217-1229. PubMed ID: 37211579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
    Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
    Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
    Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes.
    Hinnen D; Strong J
    Diabetes Spectr; 2018 May; 31(2):145-154. PubMed ID: 29773934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
    Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
    BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.
    Kis JT; Nagy G; Kovacs G
    Diabetes Ther; 2021 Sep; 12(9):2517-2529. PubMed ID: 34357560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
    Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
    Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
    Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
    Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
    Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.